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996Factors associated with primary vein graft occlusion
in a multicenter trial with mandated ultrasound
surveillance
Lawrence Oresanya, MD,a Anil N. Makam, MD, MSc,b Michael Belkin, MD,c Gregory L. Moneta, MD,d
and Michael S. Conte, MD,a San Francisco, Calif; Dallas, Tex; Boston, Mass; and Portland, Ore
Objective: Even in the setting of duplex ultrasound (DUS) surveillance, a signiﬁcant number of lower extremity vein
bypass grafts (LEVBGs) become occluded as a ﬁrst event. We sought to identify factors that may contribute to these
primary occlusions.
Methods: This was a retrospective analysis of the Project of Ex Vivo Graft Engineering via Transfection III (PREVENT
III) multicenter randomized clinical trial, in which 1404 patients with critical limb ischemia (CLI) underwent LEVBG
with 1-year follow-up. Subjects were to undergo DUS at regular intervals (1, 3, 6, and 12 months), with reintervention
based on prespeciﬁed DUS criteria. Patients who had nontechnical graft occlusion as the initial graft-related event were
identiﬁed, and multivariate analysis was used to determine factors associated with primary graft occlusion.
Results: Primary vein graft occlusion occurred in 200 subjects and accounted for 36% of all primary patency events and
64% of all graft occlusions in the trial. Primary occlusion events were evenly distributed throughout the ﬁrst postoperative
year. Rates of recurrent CLI, loss of secondary patency, and major amputation in those with primary occlusion were 55%,
79%, and 22% respectively as compared to 18%, 10%, and 10% for subjects without primary occlusion (P < .001). On
multivariate analysis, African-American race (subdistribution hazard ratio [SHR], 1.50; 95% conﬁdence interval [CI],
1.06-2.12), a graft diameter <3 mm (SHR, 2.31; 95% CI, 1.33-4.01), and nonadherence with ultrasound surveillance
(SHR, 1.58; 95% CI, 1.10-2.27) were independently associated with primary graft occlusion. Of the 123 subjects who
received their last scheduled surveillance DUS prior to a primary occlusion event, 39 had a critical ultrasound abnormality
identiﬁed but failed to undergo graft revision, while 84 had no critical ultrasound abnormality identiﬁed. Among these 84
subjects, female gender (SHR, 1.65; 95% CI, 1.07-2.54), and graft diameter <3 mm (SHR, 2.12; 95% CI, 1.03-4.37)
were independent factors associated with unheralded graft occlusion.
Conclusions: Among patients undergoing LEVBG for CLI, almost half of primary patency events are occlusions even in
the setting of a DUS surveillance protocol. African Americans, patients with smaller-diameter grafts, and those who are
nonadherent with surveillance ultrasound are at increased risk. Failure to intervene on critical ﬁndings, and lack of
sensitivity of DUS threshold criteria to predict thrombosis, are also important contributors. These ﬁndings suggest that
prevention of vein graft thrombosis requires further improvements in risk stratiﬁcation, surveillance, and the timing of
reinterventions. (J Vasc Surg 2014;59:996-1002.)For patients with critical limb ischemia (CLI), the
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5% when grafts remain patent.1 Given these poor out-
comes, a strategy of graft surveillance with pre-emptive
revision is frequently employed with the aim of preventing
graft occlusion.
Duplex ultrasound (DUS) surveillance identiﬁes graft
stenosis and ﬂow abnormalities that are associated with
increased risk of graft occlusion.2-4 These lesions can be
intervened upon to prevent graft occlusion. Surgical revi-
sion of “at-risk” grafts has been shown to signiﬁcantly
improve secondary patency rates when compared with revi-
sion of occluded grafts. The 1-year patency rates following
revision of grafts at risk of thrombosis is over 60%,5 while
less than one-third of grafts that are revised after an occlu-
sion remain patent 1 year following the initial bypass.6,7
Although the strategy of LEVBG surveillance and pre-
emptive graft revision has been widely adopted, a signiﬁ-
cant number of bypass grafts become occluded as a ﬁrst
event. Graft thrombosis that occurs prior to any attempted
revision is termed primary occlusion. Published studies of
patients undergoing LEVBG with planned DUS surveil-
lance and graft revision report a primary occlusion rate
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whether surveillance ultrasounds predict graft thrombosis,
the factors accounting for primary graft occlusion in the
setting of DUS surveillance with a reintervention protocol
are not well understood.
Using the Project of Ex Vivo Graft Engineering via
Transfection III (PREVENT III) database, we examined
factors associated with primary occlusion of LEVBG. We
hypothesized that in this cohort of 1404 subjects with
CLI who underwent lower extremity bypass with autolo-
gous vein, primary graft occlusion would be associated
with speciﬁc patient and anatomic factors, as well as with
DUS surveillance protocol compliance.METHODS
Study population and design. To examine factors ac-
counting for primary bypass graft occlusion, we performed
a retrospective cohort study of the PREVENT III database.
The PREVENT III database is composed of 1404 patients
with CLI undergoing lower extremity bypass with an
autologous vein graft. This database was assembled during
the conduct of a phase III randomized controlled trial that
failed to show a beneﬁt for edifoligide in lowering the rate
of vein graft failure. The database, however, contains
important information on subject demographics, medical
history, bypass graft characteristics, postoperative graft sur-
veillance ﬁndings, postoperative complications, and adjudi-
cated clinical outcomes. Subjects were followed for 1 year
with clinical visits at 1, 3, 6, and 12 months postopera-
tively, during which ultrasound surveillance of the bypass
graft was performed. When graft abnormalities were iden-
tiﬁed by clinical evaluation or ultrasound, angiograms
were performed, and a predeﬁned algorithm was used to
determine the need for graft revision. All incidents of graft
occlusion, graft revision, major amputation, and death
occurring during the follow-up period were adjudicated
by a blinded clinical events committee (CEC). Complete
details of the PREVENT III protocol have been previously
reported.10
Predictors. Potential predictors of primary vein graft
occlusion examined included patient characteristics, bypass
graft characteristics, and nonadherence with scheduled ul-
trasound surveillance. The patient characteristics evaluated
were age, gender, African-American race, tissue loss, car-
diovascular disease risk factors (smoking, diabetes mellitus,
hypertension, and dialysis-dependent renal failure), anti-
platelet medication use, anticoagulant medication use,
treatment with edifoligide, and a prior history of infrain-
guinal bypass. The graft characteristics assessed were graft
diameter (measured intraoperatively at the narrowest point
on distension: #3 mm, 3 mm to 3.49 mm, $3.5 mm),
graft length (<40 cm, 40 to 50 cm, 51 to 60 cm, >60 cm),
graft type (small saphenous vein, arm vein, or spliced vein
as opposed to single-segment greater saphenous vein),
graft inﬂow (common femoral artery, superﬁcial femoral
artery, popliteal), and graft outﬂow (popliteal, tibial,
pedal).We also assessed the effect of noncompliance with ul-
trasound surveillance on primary graft occlusion. In doing
this, we assumed that surveillance ultrasounds would most
likely predict graft occlusion in the time period immedi-
ately following the planned ultrasound. Therefore, non-
adherence to the 1-month (30 to 60 days), 3-month (61
to 120 days), and 6-month (121 to 210 days) surveillance
ultrasounds was evaluated as a predictor of primary graft
occlusion in the periods from 61 to 120 days, 121 to
210 days, and 211 to 365 days, respectively. Ultrasounds
performed outside of scheduled surveillance visits, such as
for short follow-up of a previously identiﬁed abnormality,
were not considered for analysis in this study.
Outcomes. Primary vein graft occlusion was deﬁned as
any bypass graft occlusion event occurring in subjects who
had not previously undergone a graft revision. All subjects
with primary graft occlusion were identiﬁed through a re-
view of ultrasound, angiogram, and intraoperative ﬁndings.
In the PREVENT III trial, all graft failure events were
adjudicated by the CEC as technical or nontechnical. In
this study, graft occlusion events occurring as a result of
a technical failure (as adjudicated by the CEC) were
excluded from the analysis. The criteria for technical fail-
ures utilized by the CEC have been previously reported,
and included failures within 2 weeks of surgery as well as
other speciﬁc causes.10
To characterize the clinical consequences of primary
graft occlusion, we examined the 1-year incidence of recur-
rent CLI, graft revision, loss of secondary graft patency,
placement of a new graft, ipsilateral major amputation, ma-
jor adverse limb event (a major amputation [transtibial or
above] or any major vascular reintervention [thrombec-
tomy, thrombolysis, new bypass graft, jump/interposition
graft revision]), and mortality.
Statistical analysis. Comparisons between dichoto-
mous variables, categorical variables and continuous vari-
ables were performed using c2 analysis, analysis of
variance, and t-tests respectively. The Kaplan-Meier
method was used to assess outcomes at 1 year. Assess-
ment of predictors of time to primary occlusion was per-
formed using the Fine-Gray model for cause-speciﬁc
hazard functions. Death, amputation, and graft revision
were treated as competing risks. The relationship of
noncompliance to ultrasound surveillance with primary
occlusion is of a time-dependent nature. Therefore, ul-
trasound adherence was treated as a time-dependent co-
variate in a longitudinal model clustered by individual. All
variables with a P value < .2 on univariate analysis were
introduced into the multivariate Fine-Gray model to
identify independent predictors of primary graft occlu-
sion. The proportionality of hazards assumption was
tested and conﬁrmed with the Schoenfeld test.
We expected that primary occlusion would occur in
some subjects despite full adherence to the surveillance
protocol. In these subjects, primary occlusion could either
result from failure to perform timely intervention on critical
lesions identiﬁed by the surveillance protocol or be unher-
alded, occurring despite a subthreshold ﬁnding on
Table I. Characteristics of subjects in Project of Ex Vivo
Graft Engineering via Transfection III (PREVENT III)
cohort by occurrence of primary occlusion
No primary
occlusion
(n ¼ 1204)
Primary
occlusion
(n ¼ 200) P
Mean age, years 69 68 .240
African-American 203 (17) 46 (23) .035
Female 429 (36) 78 (39) .358
Tissue loss 908 (75) 138 (69) .054
Treatment with edifoligide 591 (49) 106 (53) .305
Cardiovascular risk factors
Smoking 886 (74) 147 (74) .979
Diabetes mellitus 781 (65) 119 (60) .143
Hypertension 987 (82) 159 (80) .402
Hyperlipidemia 649 (54) 117 (59) .227
Coronary artery disease 361 (30) 61 (31) .883
Prior coronary artery bypass
graft
305 (25) 44 (22) .313
Dialysis-dependent 146 (12) 24 (12) .960
Prior infrainguinal bypass 320 (27) 63 (32) .148
Antiplatelet use 1046 (87) 171 (86) .596
Anticoagulant use 238 (20) 42 (21) .686
Non-SSGSV 221 (18) 52 (26) .011
Graft diameter
>3.5 mm 682 (57) 93 (47) .011
3 mm to 3.5 mm 455 (38) 89 (45)
<3 mm 67 (6) 18 (9)
Graft length
<40 cm 285 (24) 47 (24) .856
40 cm-50 cm 329 (27) 53 (27)
51 cm-60 cm 280 (23) 43 (22)
>60 cm 310 (26) 57 (29)
Inﬂow
CFA 583 (49) 104 (52) .376
SFA 353 (29) 49 (25)
Popliteal 268 (22) 47 (23)
Outﬂow
Popliteal 401 (33) 56 (28) .292
Tibial 632 (53) 116 (58)
Pedal 171 (14) 28 (14)
CFA, Common femoral artery; SFA, superﬁcial femoral artery; SSGSV,
single-segment greater saphenous vein.
Values are given as number (%) of patients unless otherwise stated.
Table II. Revascularization end points at 1 year in
subjects with and without primary occlusion
No primary
occlusion,
No. (%)
Primary
occlusion,
No. (%) P
Recurrent CLI 218 (18) 110 (55) <.001
Graft revision 337 (28) 96 (48) <.001
New graft 60 (5) 52 (26) <.001
Major amputation 119 (10) 43 (22) <.001
Major adverse limb event 193 (16) 108 (54) <.001
Loss of secondary patency 123 (10) 157 (79) <.001
Mortality 206 (17) 22 (11) .03
CLI, Critical limb ischemia.
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the factors associated with primary occlusion, subjects
were stratiﬁed by whether threshold ultrasound abnormal-
ities were identiﬁed on the last surveillance study prior to
the occurrence of primary occlusion. Critical threshold ab-
normalities were deﬁned as severe stenosis (Vr>3.0 over an
area of stenosis), peak systolic velocity (PSV) >300 m/s, or
a mean graft velocity (MGV) <45 m/s.11 A subgroup anal-
ysis examining the association of patient and graft factors
with primary graft occlusion among subjects with no crit-
ical threshold ultrasound abnormalities prior to primary oc-
clusion (unheralded occlusions) was also then performed.
All analyses were performed using STATA 12.1 (Statacorp
LP, College Station, Tex).
RESULTS
A total of 563 primary patency events occurred in the
PREVENT III cohort during the 1-year follow-up period.
Of these events, 200 were due to primary (nontechnical)
occlusions, 62 were technical occlusions, and 301 were
graft revisions. Primary occlusions therefore accounted
for 36% of all primary patency events. The median time
to primary occlusion was 125 days (interquartile range,
83-196 days); 33 events occurred between 15 and
60 days, 66 occurred between 61 and 120 days, 57
occurred between 121 and 210 days, and 44 occurred
between 211 and 365 days.
Characteristics of cohort. The mean age of subjects
with primary occlusion was 68, 39% were female, and
23% were African-American. A non-single-segment
greater saphenous vein graft was used in 26% of subjects
with primary occlusion, and 54% of grafts were less than
3.5 mm in diameter. The distal anastomosis was to the
tibial artery or a pedal artery in 58% and 14% of subjects
with primary occlusion, respectively. Further details of the
characteristics of subjects with and without primary oc-
clusion are shown in Table I. Within a year of surgery,
patients with primary occlusion were more likely to have
poor limb-related outcomes, including increased inci-
dence of CLI and amputations. The 1-year mortality,
however, was higher for subjects who did not suffer a
primary occlusion (Table II).
Ultrasound compliance and antecedent ﬁndings.
Among the 200 subjects with primary occlusion, 16% (n ¼
33) suffered primary occlusion prior to the ﬁrst surveillance
ultrasound, and 61% (n ¼ 123) were adherent to their last
scheduled surveillance ultrasound, while 22% (n ¼ 44)
were nonadherent with the last scheduled surveillance ul-
trasound prior to the period in which primary occlusion
occurred. When comparing subjects with and without pri-
mary occlusion, we found that rates of nonadherence were
similar for the 1-month (6% vs 6%; P ¼ .9) and 3-month
(32% vs 28%; P ¼ .5) ultrasound. However, non-
adherence with the 6-month ultrasound was substantially
higher among those subjects who went on to suffer a pri-
mary occlusion (50% vs 32%; P ¼ .013; Fig).
For the 123 subjects who developed primary occlusion
despite being adherent to their last scheduled ultrasound,we found that 84 had an unheralded occlusion. In these
cases, no critical threshold ultrasound abnormalities was
identiﬁed that would have mandated graft revision on the
Fig. Rate of nonadherence with scheduled ultrasound surveillance studies by occurrence of primary occlusion within
the subsequent follow-up interval. For the 1-, 3-, and 6-month ultrasounds, occlusion events were assessed at 60 to
120 days, 121 to 210 days, and 211 to 365 days, respectively. *Nonadherence was a signiﬁcant risk factor only for the
6-month ultrasound (P ¼ .013).
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other 39 subjects had a critical abnormality on the last sur-
veillance ultrasound that was not intervened upon before
the occlusion event. Failure to intervene on at-risk grafts
may, therefore, have contributed to some subjects suffering
a primary occlusion (20% of all primary occlusion events).
Predictors of primary bypass graft occlusion.
Table III shows the results of the univariate analysis
of predictors of primary graft occlusion. In multivariate
analysis, African American race (subdistribution hazard
ratio [SHR], 1.50; 95% conﬁdence interval [CI], 1.06-
2.12), graft diameter <3.0 mm (SHR, 2.31; 95% CI, 1.33-
4.01), anastomosis to a tibial artery (SHR, 1.49; 95%
CI, 1.01-2.21), and nonadherence with surveillance
ultrasound (SHR, 1.58; 95% CI, 1.10-2.27) remained in-
dependent predictors of primary graft occlusion (Table IV).
Predictors of unheralded primary graft occlusion.
Among the 84 subjects with no critical abnormalities iden-
tiﬁed on the last surveillance ultrasound prior to primary
occlusion, multivariate analysis showed female gender
(SHR, 1.65; 95% CI, 1.07-2.54) and a graft diam-
eter <3 mm (SHR, 2.12; 95% CI, 1.03-4.37) to be inde-
pendent predictors of these unheralded occlusions
(Table V).
DISCUSSION
In this study, we found that even in the setting of a
clinical trial protocol for graft surveillance, a signiﬁcant
number (14%) of LEVBG performed for CLI become
occluded prior to attempts at revision. Primary occlusions
represented a signiﬁcant proportion (36%) of all primary
patency failures. The number of primary patency events
due to primary occlusion (n ¼ 200) was almost equal tograft revisions (n ¼ 301). As expected, primary occlusion
resulted in poor limb-related outcomes, with over half of
these subjects developing recurrent CLI symptoms and
22% requiring a major amputation within the ﬁrst post-
operative year. Patient factors (African-American race),
graft-related characteristics (small graft diameter and distal
anastomosis to a tibial artery as compared with popliteal
artery), and failure to adhere with ultrasound surveillance
were signiﬁcant factors associated with primary occlusions.
The administration of the study drug (edifoligide) was not
found to be associated with the subgroup of graft failures
due to primary occlusion and is therefore unlikely to have
impacted the overall results of this study. The incidence
of primary occlusion (14%) we observed is higher than
has been reported. Two previous single-center studies
report a 7% incidence of primary occlusion despite close ul-
trasound surveillance protocols.8,9 This discrepancy may be
attributed to the greater severity of disease in our cohort,
where all subjects had CLI, 75% had tissue loss, and a sig-
niﬁcant number (24%) underwent high-risk reconstruc-
tions.12 Because subjects in the PREVENT III cohort
were from multiple (>80) centers with adjudicated data,
our ﬁnding likely represents a more realistic estimate of pri-
mary occlusion events following lower extremity bypass
with autologous vein in patients with CLI.
African-American race was found to be associated with
increased risk of primary occlusion. Other studies have
shown African-Americans to have poorer outcomes
following lower extremity revascularization. The mecha-
nism underlying this disparity remains uncertain.13 It is
possible that biologic factors such as a predisposition to
increased neointimal hyperplasia or prothrombotic states
explain these differences. Alternatively, this disparity
Table III. Predictors of primary graft occlusion,
univariate analysis
SHR (95% CI) P
Age (per 1 year) 0.99 (0.98-1.01) .421
African-American 1.62 (1.15-2.28) .006
Female 1.26 (0.93-1.72) .132
Tissue loss 0.82 (0.59-1.14) .237
Treatment with edifoligide 1.15 (0.85-1.55) .376
Cardiovascular risk factors
Smoking 0.87 (0.62-1.21) .398
Diabetes mellitus 0.82 (0.60-1.11) .192
Hypertension 1.00 (0.68-1.47) .987
Hyperlipidemia 1.15 (0.84-1.56) .380
Coronary artery disease 1.06 (0.77-1.47) .707
Prior coronary artery bypass graft 0.89 (0.62-1.26) .509
Dialysis-dependent renal failure 1.10 (0.69-1.74) .697
Prior infrainguinal bypass 1.37 (0.99-1.88) .057
Antiplatelet use 0.87 (0.57-1.32) .506
Anticoagulant use 1.07 (0.75-1.55) .699
Non-SSGSV graft 1.67 (1.20-2.34) .002
Graft diameter
>3.5 mm Referent
3 mm to 3.5 mm 1.36 (0.99-1.87) .057
<3 mm 2.57 (1.51-4.36) <.001
Graft length
<40 cm Referent
40 cm-50 cm 0.94 (0.61-1.44) .765
51 cm-60 cm 0.95 (0.61-1.49) .831
>60 cm 1.19 (0.79-1.78) .413
Inﬂow
CFA Referent
SFA 0.77 (0.53-1.12) .171
Popliteal 0.96 (0.66-1.39) .827
Outﬂow
Popliteal Referent
Tibial 1.48 (1.03-2.12) .033
Pedal 1.36 (0.83-2.23) .226
Nonadherence with ultrasound
surveillance
1.52 (1.07-2.17) .021
CFA, Common femoral artery; CI, conﬁdence interval; SFA, superﬁcial
femoral artery; SHR, subdistribution hazard ratio; SSGSV; single-segment
greater saphenous vein.
Table IV. Independent predictors of primary graft
occlusion, multivariate model
SHR (95% CI) P
African-American 1.50 (1.06-2.12) .02
Female 1.14 (0.83-1.58) .41
Diabetes mellitus 0.82 (0.59-1.13) .23
Prior infrainguinal bypass 1.33 (0.96-1.84) .09
Non-SSGSV graft 1.41 (0.99-2.02) .06
Graft diameter
>3.5 mm Referent
3 mm to 3.5 mm 1.26 (0.90-1.76) .18
<3 mm 2.31 (1.33-4.01) .00
Inﬂow
CFA Referent
SFA 0.70 (0.47-1.03) .073
Popliteal 0.86 (0.56-1.32) .494
Outﬂow
Popliteal Referent
Tibial 1.49 (1.01-2.21) .047
Pedal 1.41 (0.78-2.53) .254
Nonadherence with
ultrasound surveillance
1.58 (1.10-2.27) .013
CFA, Common femoral artery; CI, conﬁdence interval; SFA, superﬁcial
femoral artery; SHR, subdistribution hazard ratio; SSGSV, single-segment
greater saphenous vein.
Table V. Independent predictors of unheralded primary
graft occlusion, multivariate model
SHR (95% CI) P
Female 1.65 (1.07-2.54) .02
Treatment with edifoligide 1.45 (0.93-2.24) .10
Hyperlipidemia 1.46 (0.93-2.29) .10
Prior infrainguinal bypass 1.34 (0.84-2.15) .22
Antiplatelet use 0.72 (0.42-1.23) .23
Anticoagulant use 1.53 (0.95-2.46) .08
Non-SSGSV graft 1.03 (0.62-1.73) .90
Graft diameter
>3.5 mm Referent
3 mm to 3.5 mm 1.11 (0.69-1.77) .67
<3 mm 2.12 (1.03-4.37) .04
Outﬂow
Popliteal Referent
Tibial 1.68 (0.99-2.85) .06
Pedal 1.69 (0.84-3.41) .14
CFA, Common femoral artery; CI, conﬁdence interval; SFA, superﬁcial
femoral artery; SHR, subdistribution hazard ratio; SSGSV, single-segment
greater saphenous vein.
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unable to adjust, such as a lack of timely access to reinter-
vention or physician’s perceptions of the appropriateness of
intervention in a population deemed high risk. Further
research is needed to characterize the proximal factors
responsible for this observed racial disparity.
Our study identiﬁed graft diameter and the site of distal
anastomosis as potentially modiﬁable risk factors of primary
occlusion. While small-diameter grafts have repeatedly
been shown to be a predictor of graft thrombosis,14,15
anastomosis to a tibial artery as a predictor of occlusion is
less consistent. Our ﬁndings are similar to those of Gibson
et al, who showed a tibial distal anastomosis to be associ-
ated with a threefold increased risk of graft thrombosis as
compared with anastomosis to the popliteal artery.16 This
ﬁnding is likely due to the fact that patients requiring
more distal grafts have more extensive disease and poorer
outﬂow. Selection of a venous conduit with the largest
possible diameter and proximal outﬂow site wheneverpossible is still one of the best known means of reducing
primary occlusion.
In accordance with our hypotheses, failure to adhere
with ultrasound surveillance was a predictor of primary oc-
clusion. Our analysis showed that patients who suffered pri-
mary occlusion were more likely to have been nonadherent
with the surveillance ultrasound antecedent to the primary
occlusion. These ﬁndings are contrary to those of the Vein
Graft Surveillance Trial (VGST), a randomized controlled
trial, which found no patency or clinical beneﬁt for routine
DUS surveillance.17 Failure of the VGST to show beneﬁt
JOURNAL OF VASCULAR SURGERY
Volume 59, Number 4 Oresanya et al 1001for DUS surveillance may have been related to the lower
severity of illness and less complex reconstructions per-
formed in their subjects. In the VGST cohort, 66% of sub-
jects had CLI, and only 31% of bypasses were to
infragenicular targets, whereas in PREVENT III, all sub-
jects had CLI, and the majority of bypasses were to infrage-
nicular targets.
Because a signiﬁcant number of subjects had been
adherent with the last surveillance ultrasound prior to the
event, nonadherence with surveillance ultrasound only
offers a partial explanation for primary occlusion. In 39
subjects with primary occlusion, the last surveillance ultra-
sound revealed a critical ultrasound ﬁnding, but graft revi-
sion was not performed. Possible explanations for failure to
revise these grafts before primary occlusion include patient
refusal, medical ﬁtness, or failure of the graft in the interval
between the abnormal ultrasound and a scheduled revi-
sion.16 Timely reintervention may have prevented some
of these grafts from becoming occluded. On the other
hand, the 83 subjects with unheralded occlusions represent
true failings of the ultrasound surveillance and reinterven-
tion protocol. These unheralded occlusions were more
likely to occur in female patients and in subjects with
small-diameter (<3 mm) grafts. A more rapid progression
of intimal hyperplasia and graft stenosis, or greater sensi-
tivity to milder ﬂow disturbances may explain why these
grafts failed unexpectedly.
Our study has several limitations. These mainly relate
to the assessment of DUS for preventing graft thrombosis.
PREVENT III was a multicenter trial without a central ul-
trasound facility. DUS was performed individually by each
participating institution’s vascular laboratory. A lack of
uniformity and variability in the accuracy of studies per-
formed at each of these centers may have existed. Also,
while the PREVENT III protocol speciﬁed criteria for
graft revision, surgical judgment and patient preferences
were the ultimate determinants of whether intervention
was performed. Our inability to account for individual sur-
geons’ judgment regarding the need for revision and the
lack of uniformity between ultrasound facilities may have
introduced confounders that bias our results. Another lim-
itation to our study is the approach of evaluating adher-
ence to ultrasound as a dichotomous variable over ﬁxed
time intervals. Because we have not examined whether
the time to the last ultrasound or the period between ul-
trasounds was predictive of graft failure, we cannot make
inferences as to what the ideal intervals of graft surveil-
lance should be. Further studies addressing this point
could help reﬁne current DUS surveillance protocols.
There are also limitations that may have led us to under-
estimate the risk associated with nonadherence. Adher-
ence with early ultrasounds has previously been shown
to be important for preventing graft thrombosis.18,19
The high rate of adherence with the 1-month ultrasound
in PREVENT III (94% adherence for subjects with and
without primary occlusion events) means that our results
are mainly an assessment of later ultrasounds where adher-
ence rates diverged in this trial. In a real-world setting,where adherence with early ultrasounds may be lower
than observed in the PREVENT III trial, the risk of pri-
mary occlusion associated with nonadherence may there-
fore be higher than we report.
CONCLUSIONS
Primary vein graft occlusion is a signiﬁcant problem
following LEVBG for CLI. Technical factors and lack of
adherence to DUS surveillance were found to be the major
contributors to these failures. Appropriate graft selection
with utilization of large-caliber single-segment GSV
whenever possible, a well-implemented DUS surveillance
protocol, and an aggressive posture to graft revision are
important strategies for preventing these events. However,
our ﬁnding that women and subjects with small-diameter
grafts are at higher risk for unheralded occlusion highlights
the need for studies that improve the efﬁcacy of surveillance
protocols in high-risk groups.AUTHOR CONTRIBUTIONS
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